Insmed insiders dump $222 M in shares as stock slides 38% YTD

Insmed’s insider activity over the past year is defined by a single, stark metric: $221.97 million sold and no buys, yielding a buy‑sell ratio of 0.00 x. This sits well below the 0.2 x threshold that signals heavy insider selling and typically prompts investors to investigate whether the trades reflect routine compensation or a deeper lack of conviction. Ten distinct insiders executed 215 transactions, averaging roughly $1.03 million per sale, a scale that exceeds the $1 million material‑activity benchmark.

The senior‑management cohort alone accounted for $83.3 million of the total outflow. The chief executive officer sold 81 trades worth $39.9 million, the chief financial officer disposed of $23.6 million across 17 trades, and the chief operating officer liquidated $19.7 million in 12 transactions. An additional $18.2 million moved from other C‑suite officers, while non‑executive officers contributed the largest slice—$94.3 million across 64 sales. The concentration of sales among C‑suite members is a salient signal because executive trades carry more informational weight than those of directors or peripheral insiders.

Monthly patterns reveal several spikes that align with periods of heightened price weakness. In September 2024, insiders sold $18.45 million, and in February 2025 the outflow surged to $32.66 million, the highest single‑month total. The most recent quarter continued the trend, with $17.78 million sold in April 2026 and $9.76 million in February 2026. These bursts often coincided with the stock’s decline toward the lower 30 % of its 52‑week range, where the current price of $107.15 reflects a 38.5 % year‑to‑date loss. The relative strength index of 32 further underscores oversold conditions, yet the persistent insider exits suggest that the downside risk may be perceived as more than temporary.

The largest individual transactions reinforce the narrative. COO Roger Adsett sold 62,344 shares for $10.28 million on April 1, 2026, while other officer Martina M.D. Flammer executed two sales in September 2025 totaling $14.33 million. Such high‑value disposals, especially when clustered within a single day, meet the definition of a notable cluster event (three or more insiders trading within 30 days) and amplify the bearish implication.

While some insider sales are routine—stemming from equity‑compensation vesting or diversification—the sheer magnitude, the involvement of top executives, and the timing amid a steep price decline collectively point to a material erosion of insider confidence. Investors should weigh this signal against the company’s fundamentals and consider whether the market’s current discount adequately compensates for the heightened execution risk implied by the insider sell‑off.